noted frequencies of gamma oscillations recorded from the subthalamic nucleus (STN) and the clinically optimal deep brain stimulation (DBS) frequencies, expecting them to be the same or harmonics. 1,2 This would be reasonable assuming a single harmonic oscillator for each frequency band and resonance between the oscillator and DBS. This is consistent for nonlinear oscillators in loosely coupled networks as shown in mathematical models. 3 Such oscillators, including DBS, can interact when frequencies are commensurate (their ratio is a rational number) and not just harmonic. Such an oscillator can be driven at its fundamental frequency by another of a different frequency.
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RISK OF FRACTURES IN PATIENTS WITH

MULTIPLE SCLEROSIS: A POPULATION-
BASED COHORT STUDY
Ruth Dobson, Sreeram Ramagopalan, Gavin Giovannoni, London: Bazelier et al. 1 address the important issue of fracture risk in multiple sclerosis (MS) yet the discussion does not go far enough. Use of anxiolytics/hypnotics and antidepressants was strongly associated with fracture risk. These treatments have also been associated with an increased risk of both falls 2 and fractures 3 in large populationbased studies. Given the increased risk of falling associated with MS, 1 the recommendation to avoid anxiolytics/hypnotics wherever possible and to increase awareness of the falls risk associated with antidepressants in MS is important. The authors discuss short-course IV glucocorticoids, used during relapses, as a contributor to fracture risk. Although one study associated glucocorticoid use with fracture risk, 4 this has not been replicated. 5, 6 The potential for rapid improvement in mobility following glucocorticoid treatment during relapse may have beneficial effects.
A more proactive approach is required in MS. We propose all patients with MS should have formal Editors' Note: In WriteClick this week, Dr. Montgomery discusses the basal ganglia as oscillator in response to "Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease" by Tsang et al. In reference to "Risk of fractures in patients with multiple sclerosis: A population-based cohort study" by Bazelier et al., Drs. Dobson et al. stress the need to limit anxiolytics/hypnotics and antidepressants where possible in patients with multiple sclerosis given the increased risk for falls and fractures. They also emphasize that the evidence tying short-course IV glucocorticoids to fracture risk is less clear. The authors are developing a clinical risk score for fracture risk assessment in patients with multiple sclerosis.
Megan Alcauskas, MD, and Robert C. Griggs, MD Section Editor Robert C. Griggs, MD fracture risk assessment (FRAX) and falls assessment annually, with a baseline bone mineral density scan to identify those at high risk of osteoporotic fracture. Potential contributors to fracture risk should be avoided where possible, and interventions to improve both bone health and falls risk should be routine.
Author Response: Marloes T. Bazelier, Frank de Vries, Utrecht, the Netherlands: We appreciate the comments by Dobson et al. and agree with their concerns about the use of anxiolytics/hypnotics and antidepressants in patients with MS. These medication types have been associated with falls and (hip) fractures. 7, 8 However, there is no evidence that discontinuation of these drugs would prevent fractures. We also agree that epidemiologic evidence for the underlying etiology of glucocorticoid use and risk of fractures in patients with MS is unclear. 4, 6 Because patients with MS are already at risk of fracture, FRAX scores may be underestimated. Unfortunately, FRAX has not been designed specifically for patients with MS. We have recently published a clinical risk score that has been developed for fracture risk assessment in patients with MS. 9 
